Author

J. D. Bai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Biankin· 1 shared B. Sridharan· 1 shared C. V. Leiton· 1 shared C.-H. Pan· 1 shared D. K. Chang· 1 shared K. R. Shroyer· 1 shared L. F. Escobar-Hoyos· 1 shared L. Scampavia· 1 shared

Activity by Year

2019-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Biankin

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer

C.-H. Pan, Y. Otsuka, B. Sridharan, M. Woo, S. Babu, C. V. Leiton, J. D. Bai, D. K. Chang, A. Biankin, L. Scampavia, T. Spicer, L. F. Escobar-Hoyos, K. R. Shroyer

This study identifies K17 as a biomarker for PDAC and shows that PPT, a microtubule inhibitor, is more effective against K17-expressing PDAC cells when combined with Gemcitabine.

bioRxiv · Oct 11, 2019Cancer Biology